Keeping Up with the Diabetes Technology: 2016 Endocrine Society Guidelines of Insulin Pump Therapy and Continuous Glucose Monitor Management of Diabetes
- 715 Downloads
Purpose of Review
Decades after the invention of insulin pump, diabetes management has encountered a technology revolution with the introduction of continuous glucose monitoring, sensor-augmented insulin pump therapy and closed-loop/artificial pancreas systems. In this review, we discuss the significance of the 2016 Endocrine Society Guidelines for insulin pump therapy and continuous glucose monitoring and summarize findings from relevant diabetes technology studies that were conducted after the publication of the 2016 Endocrine Society Guidelines.
The 2016 Endocrine Society Guidelines have been a great resource for clinicians managing diabetes in this new era of diabetes technology. There is good body of evidence indicating that using diabetes technology systems safely tightens glycemic control while managing both type 1 and type 2 diabetes.
The first-generation diabetes technology systems will evolve as we gain more experience and collaboratively work to improve them with an ultimate goal of keeping people with diabetes complication and burden-free until the cure for diabetes becomes a reality.
KeywordsContinuous glucose monitoring Type 1 diabetes Type 2 diabetes Insulin pump Hybrid closed-loop
This manuscript is made possible by grants from International Society for Pediatric and Adolescent Diabetes (ISPAD), Juvenile Diabetes Research Association International (JDRF), and The Leona M. and Harry B. Helmsley Charitable Trust. We would like to thank Ela Pinar for her assistance in text formatting.
Compliance with Ethical Standards
Conflict of Interest
Alfonso Galderisi received research device support from Dexcom, Inc., USA.
Elise Schlissel has no conflict of interest.
Eda Cengiz is a speaker for NovoNordisk and serves on the advisory board for Novo Nordisk, MannKind, Adocia, and Lexicon.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 3.•• Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med. 2010;363(4):311–20. The results of the landmark clinical trial demonstrated that sensor-augmented pump therapy improves glycemic control significantly in adult and pediatric subjects with inadequately controlled type 1 diabetes as compared to insulin therapy.Google Scholar
- 4.Panel FCCaCTD. FDA Executive Summary. Dexcom G5 Mobile Continuous Glucose Monitoring System, Dexcom, Inc. July 21, 2016 meeting of the Clinical Chemistry and Clinical Toxicology Devices Panel P120005/S041.Google Scholar
- 5.Peters AL, Ahmann AJ, Battelino T, Evert A, Hirsch IB, Murad MH, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(11):3922–37.CrossRefPubMedGoogle Scholar
- 10.Pickup JC, Reznik Y, Sutton AJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and meta-regression of randomized controlled trials. Diabetes Care. 2017;40(5):715–22.CrossRefPubMedGoogle Scholar
- 11.(ICER) IFCaER. Controversies in the Management of Patients with Type 2 Diabetes. 2014.Google Scholar
- 12.Berthe E, Lireux B, Coffin C, Goulet-Salmon B, Houlbert D, Boutreux S, et al. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. Horm Metab Res. 2007;39(3):224–9.CrossRefPubMedGoogle Scholar
- 24.•• Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA. 2017;317(4):371–8. The randomized clinical multi-center trial results demonstrated the improvement in glycemic control for subjects with T1D using MDI therapy with CGM as compared to no CGM use Google Scholar
- 25.Lind M, Polonsky W, Hirsch IB, Heise T, Bolinder J, Dahlqvist S, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial. JAMA. 2017;317(4):379–87.CrossRefPubMedGoogle Scholar
- 26.•• Ruedy KJ, Parkin CG, Riddlesworth TD, Graham C, Group DS. Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin: results From the DIAMOND Trial. J Diabetes Sci Technol. 2017:1932296817704445. The subgroup analysis from the DIAMOND Trial showed favorable impact of CGM use in improving HbA1c in subjects with T1D and T2D on MDI as compared to non-CGM use while managing diabetes. Google Scholar
- 36.•• Foster NC, Miller KM, Tamborlane WV, Bergenstal RM, Beck RW, TID Exchange Network. Continuous glucose monitoring in patients with type 1 diabetes using insulin injections. Diabetes Care. 2016;39(6):e81–2. The TIDExchange Registry data suggest that CGM can be beneficial for insulin injection users across all age-groups to achieve optimized metabolic control of TID.Google Scholar
- 37.Administration USFD. The 670G system—P160017—approval letter. 2016.Google Scholar
- 38.•• Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19(3):155–63. The study by Garg et al. presents findings from the first FDA approved hybrid closed-loop system in the USA Google Scholar
- 40.Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(7):501–12.CrossRefPubMedGoogle Scholar
- 41.Tauschmann M, Allen JM, Wilinska ME, Thabit H, Stewart Z, Cheng P, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care. 2016.Google Scholar
- 42.Thabit H, Elleri D, Leelarathna L, Allen J, Lubina-Solomon A, Stadler M, et al. Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes. Lancet. 2015;385(Suppl 1):S96.CrossRefPubMedGoogle Scholar
- 43.Brown SA, Breton MD, Anderson SM, Kollar L, Keith-Hynes P, Levy CJ, et al. Overnight closed loop control improves glycemic control in a multicenter study of adults with type 1 diabetes. J Clin Endocrinol Metab. 2017.Google Scholar
- 45.•• Cengiz E, Bode B, Van Name M, Tamborlane WV. Moving toward the ideal insulin for insulin pumps. Expert Rev Med Devices. 2016;13(1):57–69. The overview of insulin analog use in pumps, findings from the innovative ultra-fast acting insulin analog research and their integration in to the closed-loop system are summarized Google Scholar
- 47.• Miller KM, Foster NC, Beck RW, Bergenstal RM, DuBose SN, DiMeglio LA, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care. 2015;38(6):971–8. The T1D Exchange Registry data by Miller et al. investigated the current status of glycemic control in subjects with T1D in the USA and revealed that 70% of patients have inadequate glycemic control Google Scholar
- 50.Weinstock RS, Schütz-Fuhrmann I, Connor CG, Hermann JM, Maahs DM, Schütt M, et al. Type 1 diabetes in older adults: comparing treatments and chronic complications in the United States T1D Exchange and the German/Austrian DPV registries. Diabetes Res Clin Pract. 2016;122:28–37.CrossRefPubMedGoogle Scholar